

INVERNESS MEDICAL INNOVATIONS INC  
Form 8-K  
March 02, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934  
Date of report (Date of earliest event reported): March 2, 2010  
Inverness Medical Innovations, Inc.  
(Exact name of registrant as specified in its charter)**

**Delaware**

**001-16789**

**04-3565120**

(State or other jurisdiction  
of incorporation)

(Commission file number)

(IRS Employer  
Identification No.)

**51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453**

(Address of principal executive offices)

Registrant's telephone number, including area code: **(781) 647-3900**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Inverness Medical Innovations, Inc. (the Company) is filing this Current Report on Form 8-K to furnish certain consolidated financial statements of Laboratory Specialists of America, Inc., which the Company acquired on February 17, 2010, pursuant to Rule 3-10(g) under Regulation S-X.

**Item 7.01 Regulation FD Disclosure.**

**Item 9.01 Financial Statements and Exhibits.**

Exhibit 99.1 incorporated by reference herein provides the following consolidated financial statements of Laboratory Specialists of America, Inc.:

Report of independent registered public accounting firm dated February 25, 2010;

Consolidated balance sheet as of December 31, 2009;

Consolidated statement of income for the year ended December 31, 2009;

Consolidated statement of changes in divisional equity for the year ended December 31, 2009;

Consolidated statement of cash flows for the year ended December 31, 2009; and

Notes to consolidated financial statements.

(d) *Exhibits.*

**Exhibit No. Description**

|       |   |
|-------|---|
| 99.1* | Consolidated financial statements of Laboratory Specialists of America, Inc. for the year ended December 31, 2009 |
|-------|---|

\* furnished  
herewith

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVERNESS MEDICAL INNOVATIONS,  
INC.

BY: /s/ Jay McNamara

Jay McNamara

Senior Counsel    Corporate & Finance

Dated: March 2, 2010

---

**EXHIBIT INDEX**

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| 99.1*              | Consolidated financial statements of Laboratory Specialists of America, Inc. for the year ended December 31, 2009 |

\* furnished  
herewith